Impact of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Renal Function in Patient with Heart Failure

Impact of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Renal Function in Patient with Heart Failure

Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor is a recently introduced oral agent to treat renal anemia, but its clinical implications on renal functioning in patients with heart failure remains unknown. We studied an 81-year-old man with heart failure with mildly reduced ejection f...

Full description

Bibliographic Details
Main Authors:	Teruhiko Imamura, Yohei Ueno, Koichiro Kinugawa
Format:	Article
Language:	English
Published:	MDPI AG 2021-12-01
Series:	Journal of Cardiovascular Development and Disease
Subjects:	heart failure chronic kidney disease kidney
Online Access:	https://www.mdpi.com/2308-3425/8/12/189

Similar Items

Impact of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Heart Failure with Preserved Ejection Fraction
by: Teruhiko Imamura, et al.
Published: (2021-12-01)

Efficacy of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Clinical Parameters in Patients with Heart Failure
by: Mayu Yazaki, et al.
Published: (2024-01-01)

Successful Conversion from Conventional Potassium Binder to Sodium Zirconium Cyclosilicate in a Patient with Refractory Constipation
by: Teruhiko Imamura, et al.
Published: (2022-05-01)

Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia
by: Jing Li, et al.
Published: (2022-10-01)

Impact of Sodium Zirconium Cyclosilicate Therapy Cessation in Patients with Systolic Heart Failure
by: Teruhiko Imamura, et al.
Published: (2022-09-01)

Cardiovascular Protective Effects of Oral Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat in the Treatment of Type 4 Cardiorenal-Anemia Syndrome: Protocol of a Randomized Controlled Trial
by: Yumin Wen, et al.
Published: (2022-04-01)

Clinical Implications of Sodium Zirconium Cyclosilicate Therapy in Patients with Systolic Heart Failure and Hyperkalemia
by: Teruhiko Imamura, et al.
Published: (2021-11-01)

Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure
by: Masaki Nakagaito, et al.
Published: (2021-07-01)

Acute Heart Failure in a Patient with Occult Barlow’s Disease Receiving Bevacizumab
by: Toshihide Izumida, et al.
Published: (2021-09-01)

Impact of HIF prolyl hydroxylase inhibitors in heart failure patients with renal anemia
by: Takahiro Kambara, et al.
Published: (2024-03-01)

Doppler Echocardiography-Guided Heart Rate Modulation Therapy Using Ivabradine in a Patient with Systolic Heart Failure
by: Teruhiko Imamura, et al.
Published: (2022-01-01)

Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis
by: Lei Tian, et al.
Published: (2024-12-01)

THE VALUE OF RENAL DYSFUNCTION IN PATIENTS WITH ACUTE DECOMPENSATED HEART FAILURE
by: I.I. Gorda
Published: (2016-12-01)

Predictors and Outcomes of SGLT2 Inhibitor Discontinuation in a Real-World Population after Hospitalization for Heart Failure
by: Masaki Nakagaito, et al.
Published: (2023-03-01)

Adaptive Servo-Ventilation as a Novel Therapeutic Strategy for Chronic Heart Failure
by: Teruhiko Imamura, et al.
Published: (2022-01-01)

Repeated serum creatinine measurement in primary care: Not all patients have chronic renal failure
by: Delicia Gentille Lorente, et al.
Published: (2015-07-01)

Risk Factors for Rapid Recurrence of Hyperkalemia following Cessation of Sodium Zirconium Cyclosilicate
by: Teruhiko Imamura, et al.
Published: (2022-11-01)

Management of hyperkalaemia in acute kidney injury in a heart failure patient with patiromer
by: Jonathan Slawik, et al.
Published: (2020-10-01)

Prevention of chronic kidney disease progression in patients with acute decompensation of chronic heart failure
by: V. V. Davydov, et al.
Published: (2019-04-01)

Successful Management of Osimertinib-Induced Heart Failure
by: Atsuko Fukuo, et al.
Published: (2022-02-01)

Association of Circulating Tissue Inhibitor of Metalloproteinases‐1 and Procollagen Type III Aminoterminal Peptide Levels With Incident Heart Failure and Chronic Kidney Disease
by: Wolfgang Lieb, et al.
Published: (2019-04-01)

A Novel Choice to Correct Inflammation-Induced Anemia in CKD: Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat
by: Zhipeng Yan, et al.
Published: (2020-08-01)

Markers of fibrosis in ischemic chronic heart failure and renal dysfunction
by: V. D. Syvolap, et al.
Published: (2015-06-01)

Cardiac Biomarkers and Risk of Incident Heart Failure in Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study
by: Nisha Bansal, et al.
Published: (2019-11-01)

Sacubitril/valsartan in heart failure and end‐stage renal insufficiency
by: Alex Heyse, et al.
Published: (2019-12-01)

Preliminary Report of Intravenous Tolvaptan Sodium Phosphate (Samtas<sup>®</sup>) Treatment in Decompensated Heart Failure
by: Makiko Nakamura, et al.
Published: (2024-01-01)

Predictors of adverse events in patients with ischemic chronic heart failure with reduced ejection fraction and renal dysfunction
by: D. A. Lashkul
Published: (2016-06-01)

Acute kidney injury worsens outcomes in acute decompensation of chronic heart failure
by: V. V Davydov, et al.
Published: (2017-12-01)

Impact of Sodium Zirconium Cyclosilicate Therapy on Nutrition Status in Patients with Hyperkalemia
by: Teruhiko Imamura, et al.
Published: (2022-12-01)

Factors Associated with Recurrent Heart Failure during Incorporating SGLT2 Inhibitors in Patients Hospitalized for Acute Decompensated Heart Failure
by: Masaki Nakagaito, et al.
Published: (2022-08-01)

Association of anaemia and all‐cause mortality in patients with ischaemic heart failure varies by renal function status
by: Anping Cai, et al.
Published: (2021-06-01)

Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients
by: Bin Wang, et al.
Published: (2020-01-01)

Characteristics of Patients with Heart Failure and Advanced Chronic Kidney Disease (Stages 4–5) Not Undergoing Renal Replacement Therapy (ERCA-IC Study)
by: Sandra Valdivielso Moré, et al.
Published: (2023-03-01)

CARDIORENAL INTERACTION IN DECOMPENSATED CHRONIC HEART FAILURE
by: Zh. D. Kobalava, et al.
Published: (2016-05-01)

Relationship between severity of mitral regurgitation and renal function in patients with ischemic chronic heart failure
by: D. A. Lashkul
Published: (2015-10-01)

Role of renin–angiotensin–aldosterone system inhibitors in heart failure and chronic kidney disease
by: Namrata Singhania, et al.
Published: (2020-11-01)

Initial Experience of Vericiguat Treatment in Patients with Heart Failure and Reduced Ejection Fraction
by: Makiko Nakamura, et al.
Published: (2023-06-01)

Management and outcomes of heart failure patients with CKD: experience from an inter‐disciplinary clinic
by: Mai Nguyen, et al.
Published: (2020-10-01)

Progression of valve heart disease in a cohort of patients undergoing renal replacement therapy
by: Maria Eduarda Cavalcanti Tompson, et al.
Published: (2023-11-01)

Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease
by: In-Jeong Cho, et al.
Published: (2021-12-01)